About

SANTHERA

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to developing medicines to meet the needs of patients living with mitochondrial disorders and other rare diseases.

Our focus

We are focusing on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options, such as Leber’s hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), Congenital muscular dystrophy (CMD) and Primary progressive multiple sclerosis (PPMS).

We have dedicated more than a decade to researching potential treatments in our ongoing mission to make effective medicines available for these often overlooked, life-altering diseases. We are passionate about improving patients’ quality of life and are well on the way to becoming leaders in rare mitochondrial and neuromuscular disorders.

Our history

Santhera Pharmaceuticals was founded in September 2004 through the merger of two start-up biotech companies, MyoContract AG (Switzerland) and Graffinity Pharmaceuticals AG (Germany).

Santhera’s headquarters are located in Liestal, Switzerland (near Basel), with subsidiaries in Germany, the UK, Italy, the Netherlands, Liechtenstein, the US and Canada.

Santhera’s shares have been listed on the SIX Swiss Exchange under the ticker “SANN” since November 2006. 

From the beginning, we have been committed to helping patients through the discovery, development and commercialization of medicines.  Since 2004, we have developed our pipeline by conducting numerous clinical studies in Europe and North America.

In September 2015, we received our first approval, the European Marketing Authorization, for Raxone in the treatment of patients with LHON. This makes Raxone the first and only medicine to be approved for this condition. Indeed, it is the first to be approved for any mitochondrial disorder: a major milestone in addressing the unmet medical need represented by this group of rare diseases.

Meet our Board of Directors

Elmar Schnee

Chairman of the Board and Member of the Compensation Committee

Read more

Martin Gertsch

Vice-Chairman of the Board and Chairman of the Audit Committee

Read more

​Philipp Gutzwiller

Board Member and Member of the Audit Committee

Read more

Thomas Meier

Board Member, Delegate of the Board and Chief Executive Officer

Read more

Patrick Vink

Board Member and Chairman of the Compensation Committee

Read more

Meet our Executive Management team

Thomas Meier

Chief Executive Officer, Board Member and Delegate of the Board

Read more

Christoph Rentsch

Chief Financial Officer

Read more

Oliver Strub

General Counsel & Secretary to the Board, EVP

Read more

Günther Metz

Head Business Development, EVP

Read more

Giovanni Stropoli

Chief Commercial Officer Europe & ROW, EVP

Read more

Kristina Sjöblom Nygren

Chief Medical Officer & Head Development, EVP

Read more

Todd Bazemore

Chief Operating Officer, EVP, Santhera Pharmaceuticals (USA), Inc.

Read more